相关实验视频

Updated: Jan 13, 2026

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

杜普森特在囊性纤维化相关慢性鼻炎与鼻多重症中的有效性:试点研究

Piero Giuseppe Meliante^1,2,3, Edoardo Covelli¹, Giuseppe Cimino⁴

¹Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, "Sant'Andrea" Hospital, "Sapienza" University, Rome, Italy.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery

|January 11, 2026

概括

杜皮森特在治疗囊性纤维化 (CF) 患者的慢性鼻炎与鼻多重症 (CRSwNP) 中表现有前途. 这种治疗实现了与非CF患者相比的显著症状改善.

科学领域:

肺部病理学肺部病理学
耳鼻喉科耳鼻喉科耳鼻喉科
免疫学免疫学免疫学

背景情况:

囊性纤维化 (CF) 患者经常患上与鼻多重症 (CRSwNP) 相关的慢性鼻炎,导致生活质量低下和感染风险增加.
目前CF中CRSwNP的治疗方法往往不足,与非CF患者相比,手术复发率更高.
在CF相关的CRSwNP中,尤其是2型炎症患者中,Dupilumab (Dupixent) 的疗效在很大程度上尚未被探索.

研究的目的:

评估Dupixent在治疗囊性纤维化患者中CRSwNP的有效性.
为了比较Dupixent治疗CF患者的结果与非CF患者的匹配队列.

主要方法:

进行了一项非随机的单中心试验,注册了CF患者和非CF对照.
使用中鼻结局测试22 (SNOT-22) 和鼻息肉评分 (NPS) 评估症状严重程度.
测量是在治疗前和治疗开始后1个月和6个月进行的.

主要成果:

6个月后,Dupixent在CF和对照组中显著降低了SNOT-22分数 (p=0.031).
6个月后,NPS得分显示CF组的非显著改善,但对照组的显著减少.
在6个月后,CF和对照组之间没有观察到SNOT-22或NPS得分的统计学上显著差异.

结论:

杜皮森特证明了在CF患者中管理CRSwNP的潜力,在统计学上显著的SNOT-22得分改善与非CF患者相比.
虽然NPS得分在CF患者中没有显著改善,但CF和对照组的整体结果相似.
这项试点研究表明,Dupixent是CF患者中CRSwNP的可行选择,其结果与没有CF的患者相似.

关键词:

一个双重的Dupixent.生物疗法生物疗法慢性犀牛鼻炎慢性鼻炎囊性纤维化病的发生.鼻腔多重体是指鼻腔多重体.

更多相关视频

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

相关概念视频

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...